Sophiris Bio Inc. (NASDAQ:SPHS) shares traded up 8.9% on Thursday . The stock traded as high as $3.78 and last traded at $3.68, with a volume of 3,936,980 shares traded. The stock had previously closed at $3.38.

Several research analysts have weighed in on the stock. Maxim Group increased their target price on shares of Sophiris Bio from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, August 10th. Echelon Wealth Partners reaffirmed a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th.

The firm’s market capitalization is $73.44 million. The company’s 50-day moving average is $4.37 and its 200-day moving average is $2.26.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.